FDA Approves First Next-Generation Sequencing Test for Minimal Residual Disease of ALL and Multiple Myeloma
- FDA authorizes first next generation sequencing-based test to detect very low levels of remaining cancer cells in patients with acute lymphoblastic leukemia or multiple myeloma. The U.S. Food and Drug Administration. Available at https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm622004.htm. Accessed 10/2/18.
- ClonoSEQ. Adaptive Biotechnologies. Available at https://www.adaptivebiotech.com/clonoseq/patients. Accessed 10/2/18.
- Behjati S, Tarpey PS. What is next generation sequencing? Archives of Disease in Childhood Education and Practice Edition. 2013;98(6):236-238. doi:10.1136/archdischild-2013-304340.